Merck (MRK) nears a USD 6bln biotech deal to buy Terns Pharmaceuticals (TERNS), according to FT

Newsquawk StaffPublished
Newsquawk headlinesUTC

Every headline is on the live feed 20 minutes before this site.

Iranian representatives have communicated to the Trump administration a high bar for re-entering ceasefire negotiations, according to people familiar with the matter cited by WSJ/Dow Jones

PBoC sets USD/CNY mid-point at 6.8911 vs exp. 6.8819 (Prev. 6.8943)

Merck (MRK) nears a USD 6bln biotech deal to buy Terns Pharmaceuticals (TERNS), according to FT

SK Hynix (000660 KS) says HBM market is expected to remain a key driver of growth in 2026, with demand expected to expand over the mid to long term due to AI

Iranian rocket fire was monitored towards central Israel and Tel Aviv

On the Newsquawk feed at , 20 minutes before this page.

Use the PlatformFree. No signup, no card.

Context

Merck's near USD 6 billion acquisition of Terns Pharmaceuticals signals a strategic expansion into the biotech space, potentially enhancing its pipeline and market position. Given the size of the deal, it likely reflects Merck's confidence in growth opportunities within biotechnology, and could have implications for peer valuations and future M&A activity in the sector.

Related headlines

The feed had this first.

Use the Platform